Pharmacognosy intro
Oregano's therapeutic potency centers on its essential oil, dominated by the monoterpene phenols carvacrol (3-80% of EO, chemotype dependent) and thymol (1-64% of EO), supported by p-cymene, gamma-terpinene, rosmarinic acid, ursolic acid, and flavonoids including apigenin and luteolin. Six recognized chemotypes exist: carvacrol, thymol, linalool, terpinen-4-ol, p-cymene, and sesquiterpene. The European Pharmacopoeia requires a minimum of 25 mL/kg essential oil in dried herb, with quality therapeutic grade defined as carvacrol + thymol content exceeding 60% of the essential oil. Carvacrol disrupts bacterial cell membrane integrity via interaction with membrane lipids, causing leakage of ions and ATP, and inhibits quorum sensing and biofilm formation against S. aureus, P. aeruginosa, and C. albicans. Anti-inflammatory activity proceeds through NF-kappaB suppression, COX-2 and iNOS reduction, and MAPK phosphorylation inhibition across ERK, JNK, and p38 pathways. Anti-tumor effects involve modulation of lipid metabolism via HMGCR, ACC, FASN, and SREBP1 pathway regulation. Rosmarinic acid chelates metal ions and scavenges free radicals, while carvacrol directly quenches reactive oxygen species. Comprehensive reviews confirm oregano EO among the most potent botanical antimicrobials studied across the Lamiaceae family, though most evidence derives from in vitro and animal models, with human clinical trials remaining limited.